STOCK TITAN

REVIVA PHARMACEUTICALS HOLDINGS (RVPH) SEC Filings, Jun-Jul 2025

RVPH OTC
Schedule 13D/A
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
other
-
Schedule 13G
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
other
-
Rhea-AI Summary

Reviva Pharmaceuticals (Nasdaq: RVPH) entered into a $10 million registered public offering of 20 million common shares paired with 20 million five-year Series C warrants and 20 million one-year Series D warrants, all priced at $0.50 per unit.

Net proceeds of roughly $9 million will fund R&D, working capital and general corporate purposes. The warrants are immediately exercisable at $0.50, include 4.99%/9.99% ownership caps and Black-Scholes cash-out rights on fundamental transactions. Closing is expected 27 Jun 2025, subject to customary conditions, and the company agreed to 60-day lock-up on most new issuances and a 12-month restriction on variable-rate financings.

  • Placement Agent: A.G.P./Alliance Global Partners—7% cash fee on most proceeds.
  • Registration: effective S-3 (No. 333-276848), prospectus supplement filed.
  • Use of proceeds focused on pipeline advancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.73%
Tags
current report
Rhea-AI Summary

Reviva Pharmaceuticals has announced a public offering of 20,000,000 shares of common stock at $0.50 per share, along with Series C and Series D Common Warrants. The total offering value is $10 million, with expected net proceeds of $9.3 million before expenses.

Key offering details:

  • Each share comes with two warrants: one Series C warrant (5-year term) and one Series D warrant (12-month term)
  • Both warrant series have an exercise price of $0.50 per share
  • A.G.P./Alliance Global Partners serving as sole Placement Agent, receiving 7% fee (3.5% for certain investors)
  • No minimum offering requirement or escrow arrangement
  • Expected closing date: June 27, 2025

The offering represents a significant discount to the last reported share price of $0.8049 on Nasdaq (RVPH). The company notes it is a "smaller reporting company" and warns investors of potential risks, including limited warrant liquidity as no trading market exists or is planned for the warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.73%
Tags
prospectus
-
Rhea-AI Summary

Reviva Pharmaceuticals Holdings has announced a new securities offering including shares of common stock, Series C and D Common Warrants, and Pre-Funded Warrants. The offering includes:

  • Common stock (at $0.8049 per share last trading price) with accompanying warrants
  • Series C Common Warrants with 5-year expiration and immediate exercisability
  • Series D Common Warrants with 12-month expiration and immediate exercisability
  • Pre-Funded Warrants for investors who would exceed 4.99% (or 9.99%) ownership

Key Details: A.G.P./Alliance Global Partners is serving as sole Placement Agent, receiving a 7% fee (3.5% for certain investors). The offering has no minimum requirement and will terminate by June 2025 unless completed sooner. Trading under symbol RVPH on Nasdaq Capital Market, the company qualifies as a "smaller reporting company." Proceeds will be immediately available for company use, though total offering amount remains undetermined.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-53.12%
Tags
prospectus

FAQ

How many REVIVA PHARMACEUTICALS HOLDINGS (RVPH) SEC filings are available on StockTitan?

StockTitan tracks 55 SEC filings for REVIVA PHARMACEUTICALS HOLDINGS (RVPH), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for REVIVA PHARMACEUTICALS HOLDINGS (RVPH)?

The most recent SEC filing for REVIVA PHARMACEUTICALS HOLDINGS (RVPH) was filed on November 12, 2026.